GE HealthCare Technologies Inc. GEHC

NASDAQ · Healthcare · Medical - Devices

$80.64

Close on Fri, 20 Nov 2026 · market value $36.5B

What the price is betting on

Below its record

At $81, the price assumes revenue grows about 2.2% a year for five years, from $21.6B to about $23.7B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes2.2%
Analysts, next two years4.9%
Last 3 years3.8%

Revenue growth a year. The price figure comes from a reverse DCF at a 8.2% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than GEHC? Check up to 5 of your stocks at once, free, no account.

0$10B$20B$30B$21.6B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$85

Base

$95

Bull

$106

Today $81

  • Bear $85. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $95. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $106. Cash flow grows 7% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$21.8B$21.9B, on the path
  3. FY2027$22.2B$22.9B, on the path
  4. FY2028$22.7B$24.1B, on the path
  5. FY2029$23.2B$25.6B, on the path
  6. FY2030$23.7B$26.9B, on the path

Each year's revenue at 2.2% growth from $21.6B in the 12 months to September 2026.

At a glance

Healthcare · Medical - Devices · listed on NASDAQ

Revenue, FY2025
$20.6B
Growth, 3 years a year
3.8%
Cash margin
7.3%
Net debt
$5.5B
Shares, 3-year change
+1.4%
Dividend yield
0.2%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.